Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus whole brain radiotherapy for brain metastases with moderate to severe peritumoral edema
ChiCTR2000031785Phase 4Not yet recruiting
- Sponsor
- Cancer Center of Yibin Second People's Hospital
- Start
- May 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib in brain metastases (2 arms), sponsored by Cancer Center of Yibin Second People's Hospital. Primary endpoints: Change in peritumoral edema volume at Week 12 and Change in edema index at Week 12. Planned start May 2020; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
brain metastases
Beyond the preview
Go deeper on ChiCTR2000031785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031785.